SCHEMBL7128560

SCHEMBL7128560

C=C(C(=O)O)c1ccc2ncnc(Nc3ccc4nc[nH]c4c3)c2c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAF1 P04049 1/20 0.54
BRAF P15056 1/20 0.54
RIPK2 O43353 1/20 0.48
FBP1 P09467 1/20 0.47
EPHB2 P29323 1/20 0.47
MKNK1 Q9BUB5 1/20 0.47
EGFR P00533 5/20 0.46
KDM4E B2RXH2 2/20 0.45
ERBB2 P04626 2/20 0.45
ERBB4 Q15303 1/20 0.45
ADRA2A P08913 1/20 0.44
ADRA2C P18825 1/20 0.44
ADRA1D P25100 1/20 0.44
ADRA1A P35348 1/20 0.44
ADRA1B P35368 1/20 0.44
FYN P06241 2/20 0.44
SRC P12931 2/20 0.44
CDK1 P06493 2/20 0.44
DYRK1A Q13627 1/20 0.43
DYRK1B Q9Y463 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7126665 0.93 RAF1 (0.48) RAF1BRAFRIPK2FBP1EPHB2
SCHEMBL7128555 0.93 EGFR (0.47) RAF1BRAFRIPK2FBP1EPHB2
SCHEMBL7126655 0.84 FBP1 (0.46) RAF1BRAFRIPK2FBP1EPHB2
SCHEMBL7127189 0.83 EGFR (0.66) EGFRERBB2ERBB4FYNSRC
SCHEMBL7242226 0.77 EGFR (0.66) RIPK2EPHB2EGFRKDM4EERBB2
SCHEMBL8486257 0.77 RAF1 (0.55) RAF1BRAFRIPK2EGFRERBB2
SCHEMBL7127858 0.75 EGFR (0.58) EGFRERBB2
SCHEMBL7233723 0.74 EGFR (0.70) EGFRERBB2ERBB4CLK4
SCHEMBL3243684 0.73 EGFR (0.60) RAF1BRAFEGFRKDM4EERBB2
SCHEMBL31060919 0.73 EGFR (0.60) RAF1BRAFEGFRKDM4EERBB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030087881-A1 Irreversible inhibitors of tyrosine kinases BRIDGES ALEXANDER JAMES (US) 2003-05-08 US claimed
US-6153617-A Irreversible bicyclic inhibitors of tyrosine kinases WARNER-LAMBERT COMPANY (US) 2000-11-28 US claimed
US-20030087881-A1 Irreversible inhibitors of tyrosine kinases BRIDGES ALEXANDER JAMES (US) 2003-05-08 US disclosed
US-6153617-A Irreversible bicyclic inhibitors of tyrosine kinases WARNER-LAMBERT COMPANY (US) 2000-11-28 US disclosed
WO-1999006396-A1 IRREVERSIBLE BICYCLIC INHIBITORS OF TYROSINE KINASES WARNER-LAMBERT COMPANY (US) 1999-02-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030087881-A1 Irreversible inhibitors of tyrosine kinases ERBB2, ERBB3, LCK RAF1 103/4885BRAF 32/4885RIPK2 267/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.